As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.
Similar Posts
Guidance: MORE Registrations – user reference guide
A step-by-step guide on using the MORE Platform for Registrations for Submissions of device related incidents.
Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 5mg capsules, EL(26)A/11
Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure due to a potential error at the manufacturing site.
Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure
This is a precautionary measure while the MHRA conducts the safety review.
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices
This consultation invites views on proposals for recognising CE marked medical devices in Great Britain.
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2024 to 2025
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.